Was half expecting the typical 31st March strategic update tomorrow. But now I am 50:50 given the recent departure.
Other news due tomorrow, let’s see.
Acute Myeloid Leukemia (AML)A human derived mouse model of AML study was undertaken during H2 CY2022 exploring the optimal combination of decitabine and Zantrene as a low toxicity treatment for AML. Reporting on this project has been delayed as the mice treated with the optimal Zantrene and decitabine dose have controlled the growth of the cancer to such an extent that the mice have lived far longer than expected.
The results of this study will be reported in Q1 CY2023.
General Comments / Chat, page-7012
-
- There are more pages in this discussion • 4,470 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
